Janus Henderson Global Life Sciences Fund Class D (JNGLX)

57.13
Net Asset Value
+0.11%
1 Day
+4.29%
Year-to-Date
Overall Morningstar Rating
Health
Style or Category
No Load
Sales Expenses
0.82%
Expense Ratio
Average
Morningstar Risk Rating™
Investment Objective The investment seeks long-term growth of capital. The fund pursues its investment objective by investing- under normal circumstances- at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio managers believe have a life science orientation. In the fund's pursuit of companies with a life science orientation- the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector.

Performance

1 month-3.32% 3 years+3.53%
3 months+6.04% 5 years+18.54%
1 year+16.64% Since inception+11.73%
Data through --

Peer Comparisonvs. Health

 JNGLXCategory
Performance 5-yr return+18.54%+17.28%
Expense ratio0.82%1.31%
Risk 5 year sharpe ratio1.191.11
Net assets$3.8B$3.2B
Average market cap$20.0B$9.5B
Average P/E26.822.6
Portfolio turnover38%38%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyJanus Henderson
Fund manager & tenureAndrew Acker / 10 Years
Minimal initial investment$2,500.00
Minimum IRA investment$1,000.00

Holdings

U.S. stock75.09%
International stock20.75%
Fixed income2.26%
Cash1.25%
Other0.65%
Top 5 Sectors
Portfolio weighting
Healthcare 94.74%
Consumer service 3.23%
Consumer goods 0.79%
Business service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
AET Aetna3.31%
-- 3.21%
LLY Eli Lilly and Co2.97%
SHPG Shire2.91%
-- 2.85%
CELG Celgene2.56%
HUM Humana Inc2.28%
BIIB Biogen2.22%
ANTM WellPoint2.21%
NVS Novartis2.20%